TL;DR
- An Import Alert lets FDA detain a foreign firm's shipments at the U.S. border without physically testing each one, once the firm is placed under Detention Without Physical Examination (DWPE) (FDA: Import Alerts).
- Unlike a Warning Letter, an Import Alert has an immediate commercial effect — detained shipments can't enter the U.S. market until the firm is removed from the alert.
- For foreign manufacturers, an Import Alert is arguably a faster and more commercially painful lever than a Warning Letter, which relies on the firm voluntarily correcting violations with no direct border enforcement.
- This isn't a claim that Warning Letters are disappearing — both tools coexist, but foreign-facility enforcement leans more heavily on Import Alerts than domestic enforcement does, given FDA's limited on-the-ground inspection reach abroad.
Why Import Alerts Are a Sharper Tool Than Warning Letters for Foreign Facilities
A Warning Letter asks a company to fix something. An Import Alert stops that company's product at the border while it does. For a domestic manufacturer, that distinction is mostly theoretical — FDA can inspect a U.S. facility again relatively easily to verify a fix. For a foreign manufacturer, especially one FDA inspects infrequently, the Import Alert is often the enforcement action that actually changes behavior, because it has an immediate, self-executing commercial consequence that a Warning Letter alone doesn't.
How DWPE Actually Works
Under FDA's Import Alert system, a firm placed under Detention Without Physical Examination has its shipments automatically detained at the port of entry, without FDA needing to physically inspect or test each one first (FDA: Import Alerts). The burden then shifts to the importer: to get a specific shipment released, the firm generally has to provide evidence — often private laboratory testing or other documentation — that the specific shipment meets FDA requirements, an exception process handled case by case. Getting removed from the alert list entirely requires a more substantial showing that the underlying violation has been corrected, not just that one shipment happens to be compliant.
Why This Is a Stronger Lever for Foreign Facilities Specifically
FDA's inspection reach abroad is real but limited relative to the number of foreign facilities exporting to the U.S. — the agency can't physically re-inspect every foreign firm as quickly or as often as it can a domestic one. A Warning Letter to a foreign firm still relies substantially on that firm's own voluntary corrective action and FDA's ability to eventually verify it, often at the next scheduled inspection, which may be months or years out. An Import Alert doesn't wait for that verification cycle — it acts immediately and automatically at every port, for every shipment, until the firm affirmatively gets removed.
This is why compliance teams tracking foreign supplier risk often watch Import Alert status as closely as, or more closely than, Warning Letter history: a supplier can have a clean recent Warning Letter record and still be sitting under an active DWPE listing from an older, unresolved issue.
Warning Letters Haven't Gone Away — They're Doing a Different Job
None of this means Warning Letters are becoming obsolete. They remain FDA's primary tool for documenting a specific pattern of violations and putting a firm on formal notice, domestic or foreign, and they're often the action that precedes an Import Alert in the first place — a firm ignoring a Warning Letter's underlying citations is a common path onto an Import Alert list. The two tools are sequential and complementary more often than they're substitutes for each other.
What This Means for Compliance and Supply Chain Teams
A vendor qualification process that only checks Warning Letter history and skips Import Alert status is missing a meaningful part of the picture, particularly for any supplier manufacturing outside the U.S. A firm can be actively under DWPE with no recent Warning Letter at all, if the alert stems from an older finding FDA has never verified as corrected. Conversely, a firm can have a recent Warning Letter but no Import Alert, if the violations didn't rise to the level FDA associates with a border-detention risk, or if the product category isn't one FDA tracks via that specific alert.
FAQ
How does a firm get removed from an Import Alert?
The firm generally has to petition FDA and provide evidence — often through a structured process involving private laboratory analyses of multiple consecutive shipments or other documentation — that the underlying violation has been corrected, a process FDA describes in its import alert guidance materials.
Can a domestic U.S. firm be placed on an Import Alert?
Import Alerts specifically govern imported products at U.S. ports of entry, so they primarily affect foreign manufacturers and importers bringing product into the country, not a firm that only manufactures and sells domestically.
Does an Import Alert always follow a Warning Letter?
No — a firm can be placed under an Import Alert based on FDA's own findings (including from an inspection or product testing) without a prior Warning Letter, though a Warning Letter with unresolved citations is a common precursor.
Is Import Alert status public?
Yes, FDA publishes its Import Alert lists, including which firms are under DWPE for which product categories, and updates them as firms are added or removed.
Related reading
- What is an FDA Import Alert, and what does DWPE mean?
- What Are the Six Rungs of FDA's Enforcement Escalation Ladder?
- Excelvision (Fareva) FDA Warning Letter 726714 — sterile ophthalmic CGMP violations
Search the Warning Letter database →
Sources: FDA: Import Alerts, FDA: Import Program, FDA: Warning Letters. Byline: The Argus Regulatory Analysis Team. Published 2026-07-16.